Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 176 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lyrica Clear all

Conditions: Diabetic Neuropathy, Painful
Interventions: Placebo, Pregabalin, LY545694 21 mg, LY545694 49 mg, LY545694 105 mg; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: Greenbrae, California • Tustin, California • DeLand, Florida + 5 more

Conditions: Neuropathy; Radicular, Lumbar, Lumbosacral, Failed Back Surgery Syndrome, Spinal Stenosis, Herniated Disc
Interventions: Pregabalin, Sugar Pill; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Epilepsies, Partial
Interventions: pregabalin 600 mg/day, pregabalin 150 mg/day; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 63
States / cities: Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 78
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more

Conditions: Rotator Cuff Repairs, Pain Management
Interventions: Multimodal Pain Regimen, Standard of Care Pain Regimen; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Oropharyngeal Cancer, Squamous Cell Carcinoma to the Head and Neck
Interventions: Lyrica 300 mg, Placebo; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Post-operative Pain
Interventions: Placebo, Pregabalin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetic Peripheral Neuropathy, Nerve Pain
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 40 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Norfolk, Virginia

Conditions: Nicotine Dependence
Interventions: pregabalin, cigarettes; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Pain
Interventions: Placebo, Naproxen, Pregabalin; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fibromyalgia
Interventions: Pregabalin, then placebo, Placebo, then pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Healthy
Interventions: Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, fasted, Pregabalin immediate release, 300 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anesthesia, Block
Interventions: Erecto Spinae nerve block, Multimodal Analgesia; Procedure
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Osteo Arthritis Knee, Central Nervous System Sensitization
Interventions: Pregabalin 75mg; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 50 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Knee Osteoarthritis, Arthroplasty Complications, Postoperative Pain
Interventions: Dexamethasone, Acetaminophen, Lyrica, Celebrex, Meloxicam, Oxycodone, Ropivacaine; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain, Postoperative, Hernia, Inguinal
Interventions: Pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 17 Years to 75 Years · Male only
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Birmingham, Alabama • Glendale, California • Laguna Hills, California + 16 more

Conditions: Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Fibromyalgia
Interventions: placebo, pregabalin (Lyrica); Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 30
States / cities: Los Angeles, California • Santa Ana, California • Delray Beach, Florida + 18 more

Conditions: Seizure Disorder, Partial
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Compliance, Chronic Pain
Interventions: acetazolamide, Quinine, Riboflavin; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Anxious Depression, Depression
Interventions: Escitalopram, Duloxetine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Herpes Zoster, Postherpetic Neuralgia
Interventions: Pregabalin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions: Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication; Device · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more

Search by objective public record fields.

A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

Efficacy of Pregabalin in Patients With Radicular Pain

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair

A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.

Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients

The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy

GABA (Gamma Amino Butyric Acid) Medication for Tobacco

Human Experimental Models of Pain (HEMP)

An fMRI Study Of Brain Response In Patients With Fibromyalgia

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

Evaluating the Effectiveness of Bilateral ESPB in Addition to Standard Analgesia at Reducing Opioid Consumption

Pregabalin for Central Sensitization in TKA

Pre vs Post Block in Total Knee Arthroplasty (TKA)

Surgical Pain After Inguinal Hernia Repair (SPAIHR)

Quality Improvement and Practice Based Research in Neurology Using the EMR

Adolescent Fibromyalgia Study

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain

Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy